N,N'-Disalicylalethylenediamine

N,N'-Disalicylalethylenediamine

SCHEMBL187357

Oc1ccccc1/C=N/CC/N=C/c1ccccc1O.[Co]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 8/20 0.96
CA2 P00918 7/20 0.96
KDM4E B2RXH2 2/20 0.96
CA9 Q16790 6/20 0.81
CA1 P00915 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.55
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
THRB P10828 1/20 0.49
ALOX15 P16050 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CTRC Q99895 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN5 P54829 1/20 0.48
PTPN11 Q06124 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N,N'-Disalicylalethylenediamine SCHEMBL29441822 1.00 CA12 (0.96) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL1123492 1.00 CA12 (0.96) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL22229 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL711494 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL247862 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL29356999 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL4290399 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL11613427 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL18852430 0.98 CA12 (1.00) CA12CA2KDM4ECA9CA1
N,N'-Disalicylalethylenediamine SCHEMBL25402948 0.96 CA12 (0.96) CA12CA2KDM4ECA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848940-B Polycarbonate polyol compositions and methods 沙特阿美技术公司 2024-09-06 CN claimed
CN-117186376-A Flame-retardant polypropylene carbonate and preparation method and application thereof 西安石油大学 2023-12-08 CN claimed
CN-116589674-A Be used for detecting Fe 3+ Polymer fluorescent probe of (2), preparation method and application thereof 西安石油大学 2023-08-15 CN claimed
CN-116478390-A Be used for detecting CrO 42- /Cr 2 O 72- Polymer fluorescent probe of (2), preparation method and application 西安石油大学 2023-07-25 CN claimed
US-10836859-B2 Polycarbonate polyol compositions and methods SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2020-11-17 US claimed
EP-3681984-A1 METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN DIRECT INJECTED SPARK-IGNITED ENGINES WITH COBALT-CONTAINING LUBRICANT Chevron U.S.A. Inc. (US) 2020-07-22 EP claimed
WO-2019053635-A1 METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN DIRECT INJECTED SPARK-IGNITED ENGINES WITH COBALT-CONTAINING LUBRICANT CHEVRON U.S.A. INC. (US) 2019-03-21 WO claimed
US-20190078033-A1 METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN DIRECT INJECTED SPARK-IGNITED ENGINES WITH COBALT-CONTAINING LUBRICANT CHEVRON ORONITE COMPANY LLC 2019-03-14 US claimed
CN-104114605-B Method for polymer synthesis 沙特阿美技术公司 2018-06-22 CN claimed
US-20170107241-A1 SALEN COMPLEXES WITH DIANIONIC COUNTERIONS NOVOMER, INC. (US) 2017-04-20 US claimed
WO-2009025850-A2 COPOLYMERIZATION OF EPOXIDES AND CYCLIC ANHYDRIDES CORNELL RESEARCH FOUNDATION, INC. (US) 2009-02-26 WO claimed
CN-101203980-A Membrane electrode assembly for fuel cell, method for manufacturing the same, and fuel cell comprising the same ACTA SPA (IT) 2008-06-18 CN claimed
US-20080050630-A1 Membrane-Electrode Assemblies for Fuel Cell, Their Manufacture and Use and Fuel Cells Incorporating Them ACTA S.P.A. (IT) 2008-02-28 US claimed
US-20080015052-A1 Golf ball KIYOSHI ENDO 2008-01-17 US claimed
US-20070265112-A1 Golf ball SRI SPORTS LIMITED 2007-11-15 US claimed
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology KANSAS UNIVERSITY OF, THE 2007-06-14 US claimed
WO-2006133354-A2 METHODS FOR PRODUCING NANOPARTICULATE METAL COMPLEXES AND ALTERING NANOPARTICLE MORPHOLOGY UNIVERSITY OF KANSAS (US) 2006-12-14 WO claimed
EP-1191923-A4 PROPHYLACTIC, THERAPEUTIC AND INDUSTRIAL ANTIOXIDANT COMPOSITIONS ENHANCED WITH STABILIZED ATOMIC HYDROGEN/FREE ELECTRONS AND METHODS TO PREPARE AND USE SUCH COMPOSITIONS HENCEFORTH HIBERNIA INC (US) 2004-05-06 EP claimed
EP-1191923-A1 PROPHYLACTIC, THERAPEUTIC AND INDUSTRIAL ANTIOXIDANT COMPOSITIONS ENHANCED WITH STABILIZED ATOMIC HYDROGEN/FREE ELECTRONS AND METHODS TO PREPARE AND USE SUCH COMPOSITIONS Henceforth Hibernia, Inc. (US) 2002-04-03 EP claimed
WO-2000076475-A1 PROPHYLACTIC, THERAPEUTIC AND INDUSTRIAL ANTIOXIDANT COMPOSITIONS ENHANCED WITH STABILIZED ATOMIC HYDROGEN/FREE ELECTRONS AND METHODS TO PREPARE AND USE SUCH COMPOSITIONS HENCEFORTH HIBERNIA, INC. (US) 2000-12-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107241-A1 SALEN COMPLEXES WITH DIANIONIC COUNTERIONS NCLN, POLN, NCL CA12 91/4885CA2 273/4885KDM4E 4008/4885
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology NCSTN, NCLN, NCDN CA12 365/4885CA2 207/4885KDM4E 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.